Author
Ana Holley
Medical Writer
PhD
I am a medical writer with a PhD in Biomedical Sciences and more than a decade of experience in academic research. My background is in cardiovascular science, where I have worked extensively with clinical cohorts. At Elion, I draw on my research background to develop scientifically rigorous, evidence-based content for healthcare audiences. I enjoy translating complex scientific concepts into clear, engaging communications and have particular interests in scientific storytelling, evidence synthesis, publications and grant development.
I live in the Bay of Plenty with my young family, where much of my time outside work is spent on the sidelines of children’s sport, reading and keeping up with an ever-growing collection of pets and farm animals.
Areas of interest
- Cardiovascular disease
- Respiratory medicine
- Oncology
- Inflammation or immune-mediated diseases
- Women’s health
- Critical care
- Translational medicine
My Time
Publications I’ve worked on
- Whitfield PL, Hall RM, Théaude L, et al. A very-low-calorie diet (VLCD) intervention for the management of prediabetes and early Type 2 diabetes mellitus in a multi-ethnic cohort in Aotearoa New Zealand: The PROGRESS NZ feasibility study. Asia Pac J Clin Nutr. 2024;33(2):200-212. doi:10.6133/apjcn.202406_33(2).0007
- Yiu JYT, Hally KE, Larsen PD, Holley AS. neutrophil-enriched biomarkers and long-term prognosis in acute coronary syndrome: a systematic review and meta-analysis. J Cardiovasc Transl Res. 2024;17(2):426-447. doi:10.1007/s12265-023-10425-2
- Yiu JYT, Hally KE, Larsen PD, Holley AS. Increased levels of low density neutrophils (LDNs) in myocardial infarction. Acta Cardiol. 2023;78(1):47-54. doi:10.1080/00015385.2021.2015145
- Brunton-O'Sullivan MM, Holley AS, Shi B, Harding SA, Larsen PD. Cluster analysis of extracellular matrix biomarkers predicts the development of impaired systolic function within 1 year of acute myocardial infarction. Heart Vessels. 2022;37(12):2029-2038. doi:10.1007/s00380-022-02118-8
- Rogan A, O'Sullivan MB, Holley A, McQuade D, Larsen P. Can serum biomarkers be used to rule out significant intracranial pathology in emergency department patients with mild traumatic brain injury? A systemic review & meta-analysis. Injury. 2022;53(2):259-271. doi:10.1016/j.injury.2021.10.015
- Peters S, Camidge R, Dziadziuszko R, et al. Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study. Ann Oncol. 2026;37(1):92-103. doi:10.1016/j.annonc.2025.09.018
- Hutchings M, Sureda A, Bosch F, et al. Efficacy and safety of glofitamab plus polatuzumab vedotin in relapsed/refractory large B-cell lymphoma including high-grade B-cell lymphoma: results from a phase Ib/II trial. J Clin Oncol. 2025;43(36):3788-3798. doi:10.1200/JCO-25-00992
